Convertible series C preferred stock sold at $1,000.00 per preferred
By Devika Patel
Knoxville, Tenn., June 28 - NanoViricides, Inc. plans a $5 million public offering of 10% series C convertible preferred stock, according to a prospectus supplement filed Thursday with the Securities and Exchange Commission.
The company will sell 5,000 preferreds at $1,000 apiece.
The conversion price will be equal to the lesser of 85% of the 10-day daily volume weighted average trading price of the common stock preceding the conversion date or 88% of the volume weighted average trading price for the trading day immediately prior to a conversion date.
Midtown Partners & Co., LLC is the agent.
Proceeds will be used for working capital and general corporate purposes.
NanoViricides is a West Haven, Conn., biopharmaceutical company.
| Issuer: | NanoViricides, Inc.
|
| Issue: | Series C convertible preferred stock
|
| Amount: | $5 million
|
| Shares: | 5,000
|
| Price: | $1,000.00
|
| Dividends: | 10%
|
| Warrants: | No
|
| Agent: | Midtown Partners & Co., LLC
|
| Pricing date: | June 28
|
| Stock symbol: | OTCBB: NNVC
|
| Stock price: | $0.60 at close June 27
|
| Market capitalization: | $91.62 million
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
